Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated
Public ClinicalTrials.gov record NCT01025336. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study To Evaluate The Persistence Of The Antibody Response Elicited By 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Adults Who Have Previously Been Vaccinated With Either 2 Doses Of 13vPnC Or 13vPnC And 23-Valent Pneumococcal Polysaccharide Vaccine In Different Sequential Order In Study 6115A1-3010 Or 6115A1 3005
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the levels of antibodies 1 year after receiving the second vaccine dose in two groups of adults over the age of 60: (1) those who have previously received 2 doses of 13-valent pneumococcal conjugate vaccine (13vPnC) and (2) those who have previously received 1 dose of 13vPnc and 1 dose of 23-valent pneumococcal polysaccharide vaccine (23vPS). This study will also assess whether the use of the 2 vaccines, 13vPnC and 23vPS, administered in different sequential order results in different prolonged antibody levels. This study is limited to individuals who participated in either study 6115A1-3010 (NCT00574548) or 6115A1-3005 (NCT00546572).
Study identification
- NCT ID
- NCT01025336
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 962 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2009
- Primary completion
- Sep 30, 2010
- Completion
- Sep 30, 2010
- Last update posted
- Jun 19, 2012
2009 – 2010
United States locations
- U.S. sites
- 29
- U.S. states
- 16
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Chandler | Arizona | 85224 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85258 | — |
| Pfizer Investigational Site | Denver | Colorado | 80262 | — |
| Pfizer Investigational Site | Pinellas Park | Florida | 33781 | — |
| Pfizer Investigational Site | Meridian | Idaho | 83642 | — |
| Pfizer Investigational Site | Wichita | Kansas | 67207 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40536 | — |
| Pfizer Investigational Site | Kansas City | Missouri | 64114 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63104 | — |
| Pfizer Investigational Site | Rochester | New York | 14642-8410 | — |
| Pfizer Investigational Site | Cary | North Carolina | 27518 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27704 | — |
| Pfizer Investigational Site | Raleigh | North Carolina | 27609 | — |
| Pfizer Investigational Site | Raleigh | North Carolina | 27612 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45229 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44122 | — |
| Pfizer Investigational Site | Corvallis | Oregon | 97330 | — |
| Pfizer Investigational Site | Eugene | Oregon | 97401 | — |
| Pfizer Investigational Site | Carnegie | Pennsylvania | 15106 | — |
| Pfizer Investigational Site | Grove City | Pennsylvania | 16127 | — |
| Pfizer Investigational Site | Jefferson | Pennsylvania | 15025 | — |
| Pfizer Investigational Site | Penndel | Pennsylvania | 63117 | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | 15241 | — |
| Pfizer Investigational Site | Greer | South Carolina | 29651 | — |
| Pfizer Investigational Site | Mt. Pleasant | South Carolina | 29464 | — |
| Pfizer Investigational Site | Bristol | Tennessee | 37620 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37232-2581 | — |
| Pfizer Investigational Site | Austin | Texas | 78705 | — |
| Pfizer Investigational Site | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01025336, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 19, 2012 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01025336 live on ClinicalTrials.gov.